Skip to main content

Table 4 Summary cost-effectiveness findings in patients with GI-NET

From: Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

  177Lu-Dotatate BSC (Octreotide LAR) Δ
Total costs, GBP 84,990 49,289 35,701
Quality-adjusted life expectancy, QALYs 3.25 1.92 1.33
ICER, GBP per QALY gained 26,830
  1. BSC best supportive care, GI-NET gastrointestinal neuroendocrine tumor, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year